 | • レポートコード：MRC2303I0058 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、135ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の造影剤注入装置市場規模が、予測期間中に年平均6.22%で成長すると予測しています。本レポートは、造影剤注入装置の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（注入装置、消耗品）分析、注入装置種類別（シングルヘッド型注入装置、デュアルヘッド型注入装置、シリンジレス型注入装置）分析、用途別（放射線科、心臓インターベンション、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Bracco Group、Guerbet Group、Medtron AG、Bayer HealthCare LLC、ulrich GmbH & Co. KG、Nemoto Kyorindo Co. Ltd、GE Healthcare (GE Company)、Hilin Life Products、Sino Medical-Device Technology Co. Ltd、APOLLO RT Co. Ltd、Shenzen Seacrown Electromechanical Co. Ltd、Shenzhen Anke High-tech Co. Ltdなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の造影剤注入装置市場規模：製品別 - 注入装置の市場規模 - 消耗品の市場規模 ・世界の造影剤注入装置市場規模：注入装置種類別 - シングルヘッド型注入装置の市場規模 - デュアルヘッド型注入装置の市場規模 - シリンジレス型注入装置の市場規模 ・世界の造影剤注入装置市場規模：用途別 - 放射線科における市場規模 - 心臓インターベンションにおける市場規模 - その他用途における市場規模 ・世界の造影剤注入装置市場規模：地域別 - 北米の造影剤注入装置市場規模 アメリカの造影剤注入装置市場規模 カナダの造影剤注入装置市場規模 メキシコの造影剤注入装置市場規模 … - ヨーロッパの造影剤注入装置市場規模 ドイツの造影剤注入装置市場規模 イギリスの造影剤注入装置市場規模 フランスの造影剤注入装置市場規模 … - アジア太平洋の造影剤注入装置市場規模 中国の造影剤注入装置市場規模 日本の造影剤注入装置市場規模 インドの造影剤注入装置市場規模 … - 中東/南米の造影剤注入装置市場規模 南アフリカの造影剤注入装置市場規模 ブラジルの造影剤注入装置市場規模 アルゼンチンの造影剤注入装置市場規模 … - その他地域の造影剤注入装置市場規模 ・競争状況 ・市場機会・将来の動向 |
The contrast media injectors market is expected to grow at a CAGR of 6.22% during the forecast period.
The COVID-19 pandemic has had a devastating impact on the global population’s health and a significant economic impact on most countries. The volume of imaging cases in many radiology departments dropped dramatically. The COVID-19 outbreak impacted patients’ access to healthcare facilities as the pandemic forced them to wait for lifesaving imaging procedures. The pandemic also increased the waiting time for patients to have their imaging done. According to an article published by the Radiology Society of North America in April 2020, the COVID-19 pandemic profoundly impacted radiology practices across the country. The volume of diagnostic imaging and the number of CT and MRI machines installed will primarily determine the demand for contrast injectors. The easing of norms and the start of vaccination programs led to a recovery in the contrast media injectors market.
The major factors attributed to the growth of the contrast media injectors market are increasing demand for minimally invasive surgeries, technological advancements, and increasing regulatory approvals. Several advancements in contrast media injector technology have been made to reduce contrast media waste and automate data collection regarding the dose received by a patient. For example, the automated injector systems precisely collect the amount of contrast media used. Vendors offer personalized doses to patients, using the information pulled from EMR or picture archiving and communication systems (PACS). One such advancement in reducing contrast media waste is syringeless injectors.
According to the WHO updates from July 2021, cardiovascular diseases (CVDs) are the number one cause of death globally. An estimated 17.9 million each year suffer from cardiovascular diseases. Four out of five cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years. Similarly, according to the WHO 2021 fact sheet, non-communicable diseases (NCDs), also known as chronic diseases, are responsible for the death of about 41 million people each year, which was about 71% of the total deaths recorded all over the world. As per the same source, every year, over 15 million people aged between 30-69 years die due to NCDs across the world. Thus, due to the high burden of mortality due to NCDs, the demand for diagnostic procedures is increasing. As minimally invasive procedures have more advantages over traditional procedures, they are gaining traction, and thereby, the demand for contrast media injectors is expected to increase.
Most companies are developing innovative products to reduce contrast media waste and gain a competitive advantage. Bracco has developed smart syringeless injectors, which can use every drop of contrast loaded into the system for maximum economy. Smart injectors record the amount injected and the imaging protocol used and send the information to the PACS. These constant technological advancements in contrast to media injector technology are expected to boost the market during the forecast period.
However, the high cost of contrast media injectors and adverse effects of contrast agents are expected to plummet the growth of the market over the forecast period.
Contrast Media Injectors Market Trends
The CT Injector Systems Segment is Expected to Record a High CAGR in the Injectors Segment
CT injectors are expected to grow positively as the usage of CT systems has increased over the past few years. These CT systems use a dual-head injector with two syringes for initial and follow-up contrast doses during imaging. There has been constant R&D activity by major academic centers and pharmaceutical companies to develop protocols that help CT users with the advanced capabilities of newer imaging systems.
Major players are gradually implementing various strategies, such as collaborative initiatives, to remain competitive in the market. For example, In May 2022, Bayer Korea said it had started marketing MEDRAD Centargo, a computed tomography (CT) injection medical device, which received approval from the Ministry of Food and Drug Safety in January. Similarly, Ulrich Medical, a German medical technology company, presented a version of its CT motion contrast media injector designed for the American market at the RSNA in Chicago in May 2020. It was approved by the FDA and marketed in collaboration with GE Healthcare.
Such factors are expected to boost the market’s growth over the forecast period positively.
North America is Expected to Hold a Significant Share in the Market and Continue the Growth Trend During the Forecast Period
North America is expected to dominate the overall market during the forecast period, primarily due to the increasing preference for minimally invasive procedures and the increasing prevalence of chronic diseases due to changing lifestyles. The United States holds the largest market share in the region.
According to the CDC data updated in May 2021, chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. They also contribute to USD 3.8 trillion in annual healthcare costs. Six in 10 adults in the country have a chronic disease, and four in every 10 have two or more chronic diseases.
Additionally, according to Heart Disease & Stroke Statistical Fact Sheet 2020, a minimum of 40,000 infants are expected to be affected yearly by congenital heart defects in the United States. About 25% or 2.4 (per 1,000 live births) require treatment in the first year of an infant’s life.
Technological advancements in contrast media injector devices, increasing expenditure by key players, and rising regulatory approvals are also boosting the growth of the contrast media injectors market in North America.
Contrast Media Injectors Market Competitor Analysis
The contrast media injectors market is consolidated, competitive, and consists of a few major players. In terms of market share, few major players currently dominate the market. With increasing technological advancements, the high prevalence of diseases, and the increasing usage of minimally invasive surgeries, more companies are expected to enter the market in the coming years. Major players in the market are Bracco Group, GE Healthcare, Bayer HealthCare, Medtron AG, and Ulrich GmbH & Co. KG.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Minimally Invasive Surgeries
4.2.2 Technological Advancements and Increasing Number of Regulatory Approvals
4.3 Market Restraints
4.3.1 High Cost of Contrast Media Injectors
4.3.2 Adverse Effects of Contrast Agents
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Products
5.1.1 Injector Systems
5.1.1.1 CT Injector Systems
5.1.1.2 MRI Injector Systems
5.1.1.3 Cardiovascular/Angiography Injector Systems
5.1.2 Consumables
5.1.2.1 Tubing
5.1.2.2 Syringe
5.1.2.3 Other Consumables
5.2 By Type of Injectors
5.2.1 Single-head Injectors
5.2.2 Dual-head Injectors
5.2.3 Syringeless Injectors
5.3 By Application
5.3.1 Radiology
5.3.2 Interventional Cardiology
5.3.3 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bracco Group
6.1.2 Guerbet Group
6.1.3 Medtron AG
6.1.4 Bayer HealthCare LLC
6.1.5 ulrich GmbH & Co. KG
6.1.6 Nemoto Kyorindo Co. Ltd
6.1.7 GE Healthcare (GE Company)
6.1.8 Hilin Life Products
6.1.9 Sino Medical-Device Technology Co. Ltd
6.1.10 APOLLO RT Co. Ltd
6.1.11 Shenzen Seacrown Electromechanical Co. Ltd
6.1.12 Shenzhen Anke High-tech Co. Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS